Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston
3
×
boston blog main
boston top stories
deals
3
×
life sciences
national blog main
clinical trials
national top stories
san francisco blog main
abbvie
alexion pharmaceuticals
allergan
alnylam pharmaceuticals
alzheimer's disease
azacitidine
beta-thalassemia
boehringer ingelheim
crispr
cynthia collins
dacogen
decitabine
dicerna pharamceuticals
dna
editas medicine
epigenetics
epizyme
farydak
fda
flagship pioneering
fulcrum therapeutics
gene editing
hepatitis b
hepatitis b virus
hereditary transthyretin amyloidosis
insulated genomic domains
kaleido biosciences
leber congenital amaurosis type 10
mahesh karande
michelle robertson
What
medicines
3
×
research
3
×
biotech
gene
abbvie
aims
alliance
approach
based
called
caught
causing
debuts
developing
dicerna
disease
drug
drugs
editas
editing
epigenetic
epigenetics
exits
experimental
eye
field
flagship’s
genetic
hepatitis
intended
morning
new
omega
pact
partnership
pay
pharma
pharmaceuticals
producing
protein
Language
unset
Current search:
medicines
×
deals
×
boston
×
research
×
@xconomy.com
3 years ago
AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further